SAB is developing SAB-142 as a disease-modifying immunotherapy aimed at delaying the onset and progression of T1D.

Working to change the lives of people impacted by type 1 diabetes through unique disease-modifying therapies

The Constant Management of Type 1 Diabetes (T1D) Calls for Treatment Options that Address the Underlying Cause of Disease

The chronic burden of type 1 diabetes is multifaceted, impacting a person’s physical and mental well-being. Managing symptoms and potentially severe complications takes its toll on patients and caregivers alike, and it is clear there is an urgent need for treatment options that can delay the onset of T1D or modify the disease trajectory.


SAB BIO’s Lead Asset, SAB-142, Is a Disease-Modifying Therapy That Can Potentially Delay Progression of T1D

Unlike insulin or other approaches to symptom management, our work is focused on addressing the underlying cause of T1D: an over-reactive immune response that causes the immune system to mistakenly attack insulin-producing beta cells in the pancreas. SAB-142 is a treatment option that could help preserve beta cell function over time.

Learn More About Our Science

Asset 1